Protease Activated Receptors 1 and 2 Correlate Differently with Breast Cancer Aggressiveness Depending on Tumor ER Status

Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2013) E. Senkus et al.   ANNALS OF ONCOLOGY

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

(2013) A. Goldhirsch et al.   ANNALS OF ONCOLOGY

Proteinase-activated receptors (PARs) – focus on receptor-receptor-interactions and their physiological and pathophysiological impact

(2013) Frank Gieseler et al.   Cell Communication and Signaling

Protease-activated-receptor-2 affects protease-activated-receptor-1-driven breast cancer

(2013) Mohammad Jaber et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Transactivation of the PAR1-PAR2 Heterodimer by Thrombin Elicits β-Arrestin-mediated Endosomal Signaling

(2013) Huilan Lin et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Regulation of human protease-activated receptor 1 (hPar1) gene expression in breast cancer by estrogen

(2012) Zaidoun Salah et al.   FASEB JOURNAL

We Can Do It Together: PAR1/PAR2 Heterodimer Signaling in VSMCs

(2011) Rafal Pawlinski et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Protease-Activated Receptor-2 Modulates Protease-Activated Receptor-1–Driven Neointimal Hyperplasia

(2011) Leila M. Sevigny et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

PAR1 and PAR2 Couple to Overlapping and Distinct Sets of G Proteins and Linked Signaling Pathways to Differentially Regulate Cell Physiology

(2010) K. L. McCoy et al.   MOLECULAR PHARMACOLOGY

Etk/Bmx Regulates Proteinase-Activated-Receptor1 (PAR1) in Breast Cancer Invasion: Signaling Partners, Hierarchy and Physiological Significance

(2010) Irit Cohen et al.   PLoS One

Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009

(2009) A. Goldhirsch et al.   ANNALS OF ONCOLOGY

Blockade of PAR1 Signaling with Cell-Penetrating Pepducins Inhibits Akt Survival Pathways in Breast Cancer Cells and Suppresses Tumor Survival and Metastasis

(2009) E. Yang et al.   CANCER RESEARCH

Protease-Activated Receptor (PAR) 2, but not PAR1, Signaling Promotes the Development of Mammary Adenocarcinoma in Polyoma Middle T Mice

(2008) H. H. Versteeg et al.   CANCER RESEARCH